Nureca Ltd
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
- Market Cap ₹ 312 Cr.
- Current Price ₹ 327
- High / Low ₹ 435 / 198
- Stock P/E 34.7
- Book Value ₹ 206
- Dividend Yield 0.00 %
- ROCE 0.33 %
- ROE -0.36 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- The company has delivered a poor sales growth of 2.89% over past five years.
- Company has a low return on equity of -1.93% over last 3 years.
- Earnings include an other income of Rs.9.26 Cr.
- Working capital days have increased from 237 days to 403 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 5m | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 1 | 99 | 213 | 256 | 112 | 95 | 115 | 144 | |
| 0 | 1 | 1 | 90 | 152 | 200 | 127 | 106 | 124 | 139 | |
| Operating Profit | 0 | 0 | 0 | 10 | 62 | 56 | -15 | -11 | -10 | 4 |
| OPM % | 0% | 3% | 4% | 10% | 29% | 22% | -14% | -12% | -8% | 3% |
| 0 | 0 | 0 | 0 | 3 | 8 | 7 | 11 | 13 | 9 | |
| Interest | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 0 | 0 | 0 | 9 | 62 | 61 | -11 | -3 | -0 | 10 |
| Tax % | 50% | 33% | 26% | 26% | 26% | -23% | -25% | 46% | ||
| 0 | 0 | 0 | 6 | 47 | 45 | -8 | -2 | -1 | 9 | |
| EPS in Rs | 0.00 | 20.00 | 20.00 | 6,410.00 | 46.53 | 45.31 | -8.42 | -2.44 | -0.67 | 9.15 |
| Dividend Payout % | 0% | 0% | 0% | 4% | 7% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -23% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 226% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -7% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | -2% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 0 | 0 | 0 | 15 | 153 | 194 | 185 | 183 | 182 | 186 |
| 0 | 0 | 0 | 10 | 4 | 4 | 3 | 2 | 4 | 3 | |
| 0 | 0 | 1 | 9 | 19 | 11 | 8 | 9 | 10 | 14 | |
| Total Liabilities | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 | 213 |
| 0 | 0 | 0 | 1 | 3 | 10 | 8 | 6 | 8 | 13 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 1 | 34 | 62 | 97 | 4 | 11 |
| 0 | 0 | 1 | 33 | 181 | 175 | 136 | 101 | 194 | 189 | |
| Total Assets | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 | 213 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| -0 | -8 | 35 | 2 | 12 | -3 | -19 | |||
| 0 | -0 | -110 | -3 | -18 | 18 | 9 | |||
| 0 | 8 | 92 | -7 | -2 | -1 | -1 | |||
| Net Cash Flow | 0 | -0 | 17 | -9 | -8 | 14 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365 | 87 | 65 | 47 | 0 | 4 | 14 | 7 | 14 |
| Inventory Days | 0 | 101 | 590 | 93 | 135 | 174 | 154 | 156 | 163 |
| Days Payable | 233 | 849 | 33 | 32 | 13 | 23 | 27 | 26 | |
| Cash Conversion Cycle | 365 | -45 | -195 | 107 | 103 | 165 | 145 | 136 | 151 |
| Working Capital Days | 182 | -12 | -45 | 85 | 61 | 109 | 148 | 160 | 403 |
| ROCE % | 100% | 75% | 76% | 67% | 33% | -5% | -1% | 0% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12h - Nureca Limited has informed regarding Newspaper Publication.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
1d - Nureca limited has informed regarding Investor Presentation.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2d - Nureca Limited has informed regarding Investor Presentation.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Q3 FY26 (ended Dec 31, 2025): revenue +50% YoY to 39.6; 9M revenue +43% to 111.6; PAT up sharply.
-
Board Meeting Outcome for Nureca Limited Has informed Regarding Financial Results For The Quarter Ended 31St December,2025.
2d - Unaudited Q3 and nine-month standalone and consolidated results; buyback ₹19.14 crore completed; board met Jan 17, 2026.
Annual reports
Concalls
-
Jan 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Oct 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
Business Overview:[1][2]
NL is a digitally first, consumer healthcare company with presence in categories such
as home diagnostics, wellness devices, and personal fitness equipment under brands like
Dr Trust and Dr Physio. The company has 277+ Active SKUs, and 7 New Products were launched during Q1FY26